Suppr超能文献

[Clareon®人工晶状体与AutonoMe®植入系统的临床经验]

[Clinical experience with the Clareon® IOL and the AutonoMe® implantation system].

作者信息

Bedar Mohammad Seleman, Kellner Ulrich

机构信息

AugenZentrum Siegburg, MVZ Augenärztliches Diagnostik & Therapiecentrum Siegburg GmbH, Europaplatz 3, 53721, Siegburg, Deutschland.

RetinaScience, Bonn, Deutschland.

出版信息

Ophthalmologe. 2020 Nov;117(11):1100-1104. doi: 10.1007/s00347-020-01075-9.

Abstract

BACKGROUND

The AutonoMe® implantation system with a preloaded, monofocal, aspherical, hydrophobic Clareon® intraocular lens (IOL) has recently become available. The aim of this analysis was the most comprehensive review of intraoperative and postoperative outcomes to date.

METHODS

Prospective evaluation of intraoperative features in all eyes scheduled to have cataract surgery with Clareon® IOL implantation using the AutonoMe® implantation system between December 2017 and September 2018 with follow-up at 4-6 weeks. Inclusion of all patients, regardless of comorbidities and accompanying ocular surgery.

RESULTS

A total of 391 eyes were evaluated for the intraoperative analysis and 144 eyes were evaluated for postoperative follow-up. There was one IOL-associated intraoperative complication in which the posterior haptic was not correctly loaded and should not have been implanted. The best corrected distance visual acuity (BCDVA) increased from a mean of 0.33 logMAR (SD 0.21) preoperatively to 0.09 logMAR (SD 0.21) postoperatively, independent of ocular comorbidities. The BCDVA in patients without ocular comorbidities increased from 0.27 logMAR (SD 0.13) preoperatively to 0.03 logMAR (SD 0.05) postoperatively. Using the SRK®/T formula 87.5% of all eyes had a refractive error of ≤0.5 D and 98.0% had a refractive error of ≤1 D 4-6 weeks after surgery.

CONCLUSION

This study showed that using the recommended safety guidelines, the AutonoMe® system enables safe implantation of the IOL. The Clareon® IOL showed good postoperative visual outcomes and refraction results using the SRK®/T formula.

摘要

背景

最近,预装载单焦点、非球面、疏水型Clareon®人工晶状体(IOL)的AutonoMe®植入系统已投入使用。本分析的目的是对迄今为止的术中和术后结果进行最全面的综述。

方法

对2017年12月至2018年9月期间计划使用AutonoMe®植入系统植入Clareon® IOL进行白内障手术的所有患眼的术中特征进行前瞻性评估,并在4-6周时进行随访。纳入所有患者,无论其合并症和伴随的眼部手术情况如何。

结果

共有391只患眼接受了术中分析,144只患眼接受了术后随访。发生了1例与IOL相关的术中并发症,后襻未正确装载,不应植入。最佳矫正远视力(BCDVA)从术前平均0.33 logMAR(标准差0.21)提高到术后0.09 logMAR(标准差0.21),与眼部合并症无关。无眼部合并症患者的BCDVA从术前0.27 logMAR(标准差0.13)提高到术后0.03 logMAR(标准差0.05)。使用SRK®/T公式,术后4-6周时,87.5%的患眼屈光不正≤0.5D,98.0%的患眼屈光不正≤1D。

结论

本研究表明,按照推荐的安全指南使用AutonoMe®系统能够安全植入IOL。使用SRK®/T公式,Clareon® IOL显示出良好的术后视觉效果和屈光结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验